智通财经APP讯，国药一致(000028.SZ)披露2025年度前三季度业绩快报，公司实现营业收入551.24亿 元，同比下降2.38%;归属于上市公司股东的净利润9.57亿元，同比下降10.18%，相应的基本每股收益同 比下降9.95%。 2025年1-9月，分销板块实现营业收入405.94亿元，同比下降0.59%;实现净利润7.23亿元，同比下降 7.32%。第三季度，分销业务面临的政策与市场竞争压力仍然存在，但公司通过持续优化业务结构，分 销收入实现企稳回升。同时，受部分下游客户回款周期较长影响，信用减值损失计提同比增加，导致利 润下滑，但公司坚持业务调整与成本管控，利润降幅呈收窄态势。零售板块实现营业收入152.26亿元， 同比下降7.14%;实现净利润0.13亿元，同比增长133.91%。 ...

2025年1-9月，分销板块实现营业收入405.94亿元，同比下降0.59%;实现净利润7.23亿元，同比下降 7.32%。第三季度，分销业务面临的政策与市场竞争压力仍然存在，但公司通过持续优化业务结构，分 销收入实现企稳回升。同时，受部分下游客户回款周期较长影响，信用减值损失计提同比增加，导致利 润下滑，但公司坚持业务调整与成本管控，利润降幅呈收窄态势。零售板块实现营业收入152.26亿元， 同比下降7.14%;实现净利润0.13亿元，同比增长133.91%。 智通财经APP讯，国药一致(000028.SZ)披露2025年度前三季度业绩快报，公司实现营业收入551.24亿 元，同比下降2.38%;归属于上市公司股东的净利润9.57亿元，同比下降10.18%，相应的基本每股收益同 比下降9.95%。 ...

| 基本每股收益（元） | 1.72 | 1.91 | -9.95% | | --- | --- | --- | --- | | 加权平均净资产收益率 | 5.29% | 5.99% | 下降0.70个百分点 | | 总资产 | 5,055,886.26 | 4,755,586.04 | 6.31% | | 归属于上市公司股东的所有者权益 | 1,842,994.62 | 1,766,952.84 | 4.30% | | 股本 | 55,656.51 | 55,656.51 | 0.00% | | 归属于上市公司股东的每股净资产 （元） | 33.11 | 31.75 | 4.28% | 证券代码：000028、200028 证券简称：国药一致、一致B 公告编号：2025-37 国药集团一致药业股份有限公司 2025年度前三季度业绩快报 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本公告所载2025年度前三季度的财务数据仅为初步 核算数据，未经会计师事务所审计，与第三季报中披露的最终数据 可能存在差异，请投资者注意投资风险。 1、2025年前三季度主要财务 ...

国药一致发布业绩快报，前三季度营业总收入551.24亿元，同比下降2.38%。净利润9.57亿元，同比下 降10.18%。面对复杂多变的外部环境，公司将坚定不移地聚焦"开源、节流、提效"的重点方向，加速数 字化转型、深化组织变革与精细化管理、调整业务结构，持续提升经营质量与抗风险能力，实现稳健发 展。 ...

证券之星消息，10月20日医疗耗材供应链SPD板块较上一交易日上涨0.41%，建发致新领涨。当日上证指 数报收于3863.89，上涨0.63%。深证成指报收于12813.21，上涨0.98%。医疗耗材供应链SPD板块个股涨 跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301584 | 建发致新 | 29.30 | 4.46% | 18.64万 | 5.34 Z | | 301126 | 达嘉维康 | 11.75 | 3.07% | 5.35万 | 6221.88万 | | 605186 | 健摩信息 | 19.55 | 2.68% | 1.72万 | 3343.23万 | | 603122 | 合富中国 | 6.40 | 1.91% | 4.41万 | 2806.45万 | | 300288 | 朗玛信息 | 13.68 | 1.48% | 3.64万 | 4968.35万 | | 603716 | 塞力医疗 | 26.11 | 1.48% | 19.46万 | 5.03亿 | ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301015 | 百洋医药 | 27.17 | -2.96% | 5.74万 | 1.58亿 | | 301584 | C建发致 | 28.15 | -2.90% | 21.71万 | 6.15亿 | | 600833 | 第一医药 | 13.38 | -2.76% | 8.11万 | 260'T | | 301126 | 达嘉维康 | 11.13 | -2.37% | 4.04万 | 4537.69万 | | 603108 | 润达医疗 | 15.70 | -1.88% | 19.17万 | 3.00亿 | | 000705 | 浙江震元 | 9.78 | -1.41% | 13.46万 | 1.31亿 | | 002462 | 章章点 | 13.69 | -0.58% | 4.41万 | 6013.33万 | | 300937 | 药易购 | 26.53 | -0.49% | 1.29万 | 3415.25万 | | 600538 | 国发股份 ...

Core Viewpoint - The offline pharmacy industry is undergoing a significant transformation, shifting from rapid expansion to a focus on optimization and quality improvement, with many companies facing declining performance and store closures as a result of changing market dynamics and regulatory pressures [1][7]. Industry Performance - In the first half of 2025, several listed offline pharmacy companies reported weak performance, with major players like Yifeng Pharmacy, Lao Baixing, and Yixin Tang experiencing revenue declines [2]. - The retail pharmacy sector is seeing a slowdown in revenue growth, with some companies reporting negative growth for the first half of 2025, marking the end of a 20-year period of high growth [2][4]. Store Closures and Strategic Adjustments - Major pharmacy chains are closing stores to optimize their operations, with Yifeng Pharmacy closing 1,078 stores and Daclin closing 733 stores in 2024 [5]. - Guoda Pharmacy, once a member of the "10,000 store club," has closed over 1,270 stores as part of its strategic shift towards high-quality development, reducing its total store count from 10,702 to 9,569 by the end of 2024 [2][6]. Market Trends and Future Outlook - The overall retail pharmacy market is experiencing a contraction, with a significant decrease in the number of stores, dropping below 700,000 nationwide by the first quarter of 2025 [6]. - The industry is expected to undergo consolidation, with a shift from quantity expansion to quality improvement, driven by regulatory changes and market pressures [7][8]. - The rise of online pharmacy services is impacting traditional brick-and-mortar stores, but the latter are adapting by enhancing their service offerings and focusing on prescription drugs and health products [8].

Investment Rating - The report maintains an "Outperform" rating for the biopharmaceutical industry [1] Core Viewpoints - The growth of healthcare expenses, which reached 9.06 trillion yuan in 2023, is outpacing GDP growth, indicating that commercial health insurance may provide a solution to the pressures faced by the medical insurance system [3][15] - The commercial health insurance sector is expected to grow significantly, with premiums projected to reach 97.74 billion yuan by 2024, driven by low penetration rates and the need for additional funding sources [20][24] - Policies are increasingly supportive of commercial health insurance, particularly in relation to innovative drugs, which are now being included in the commercial health insurance directory [71][76] Summary by Sections Part 1: Healthcare Financing System - The healthcare financing system in China consists of government, social, and personal contributions, with social contributions being the main driver for future growth [10][15] Part 2: Growth of Health Insurance - The commercial health insurance market is expected to fill a significant funding gap, with an estimated shortfall of over 1.7 trillion yuan by 2030 [21][22] - Medical insurance is the primary source of compensation within commercial health insurance, with a compensation rate of approximately 68.79% in 2022 [27][31] Part 3: Core Products of Medical Insurance - The report highlights the importance of medical insurance as a key focus area, noting that it directly compensates for medical expenses, unlike critical illness insurance [31][35] Part 4: Policy Support for Health Insurance Development - A series of policies since 2009 have aimed to promote the development of commercial health insurance, with specific targets for market size and coverage [71][72] Part 5: Investment Recommendations - The report suggests focusing on innovative drug companies with rich pipelines, DTP pharmacies, and companies in the TPA industry, as well as innovative medical devices and high-end medical service providers [77]

Market Overview - The Shanghai Composite Index closed at 3831.66 points, above the annual line, with a decline of 1.15% [1] - The total trading volume of A-shares reached 31666.43 billion yuan [1] Stocks Breaking Annual Line - A total of 15 A-shares have surpassed the annual line today, with notable stocks showing significant deviation rates [1] - Stocks with the highest deviation rates include: - Gongyuan Co., Ltd. (8.27%) - Huayang International (7.83%) - China Automotive Technology & Research Center (5.07%) [1] Detailed Stock Performance - The following table summarizes the performance of stocks that broke the annual line on September 18: - Gongyuan Co., Ltd. (002641): Price increased by 9.95%, turnover rate 3.59%, annual line 4.29 yuan, latest price 4.64 yuan, deviation rate 8.27% [1] - Huayang International (002949): Price increased by 10.01%, turnover rate 8.81%, annual line 14.78 yuan, latest price 15.94 yuan, deviation rate 7.83% [1] - China Automotive Technology & Research Center (601965): Price increased by 5.19%, turnover rate 3.87%, annual line 18.12 yuan, latest price 19.04 yuan, deviation rate 5.07% [1] - Other stocks with lower deviation rates include: - ST Yigou (000024): Price increased by 1.05%, turnover rate 0.65%, annual line 1.92 yuan, latest price 1.92 yuan, deviation rate 0.03% [1]

处罚依据：中华人民共和国药品管理法实施条例/第九章法律责任/第七十五条药品经营企业、医疗机构未违反《药品管理法》和本条例的有关规定，并有充 分证据证明其不知道所销售或者使用的药品是假药、劣药的，应当没收其销售或者使用的假药、劣药和违法所得；但是，可以免除其他行政处罚。 处罚结果：没收违法所得24115.56元 近日，齐鲁晚报·齐鲁壹点记者从深圳市市场监督管理局官网获悉，国药控股深圳健民有限公司因销售不合格药品案，被深圳市市场监督管理局行政处罚。 处罚事由：药品违法行为。 · 营业期限至: 2032年06 ▌股东及出资信息 ·法定代表人: 牛志福 | 行政处罚决定书文号: | 深市监处罚〔2025〕福4号 | | --- | --- | | 处罚名称: | 国药控股深圳健民有限公司销售不合格药品案 | | 处罚类别: | 没收违法所得 | | 处罚事由: | 药品违法行为 | | 处罚依据: | 中华人民共和国药品管理法实施条例/第九章法律责任/第七十五条药品经济 的有关规定，并有充分证据证明其不知道所销售或者使用的药品是假药、 违法所得;但是,可以免除其他行政处罚。 | | 处罚结果: | 没收违法所得241 ...